MARATTO

erratum · Bioorganic Chemistry

Corrigendum to “Novel spirooxindole based benzimidazole scaffold: In vitro, nanoformulation and in vivo studies on anticancer and antimetastatic activity of breast adenocarcinoma” [Bioorg. Chem. 129 (2022) 106124]

Abstract

This is a critical needed correction. In Fig. 15, the image corresponding to the lung from mouse treated with 25 mg/kg was taken from the same section of the mouse that was treated with 10 mg/kg. The corrected Fig. 15 [Formula presented] Fig. 15. Microscopic pictures of H&amp;E stained lung sections from groups received (A) 4*10<sup>6</sup> cells/200 μL showing congested blood vessels (red arrows), peribronchial and interstitial aggregation (black arrows) of tumour cells admixed with MNCs. Microscopic pictures of H&amp;E stained lungs sections from treated groups (B) 10 or (c) 25 mg/kg) showing disappeared congestion with decreased numbers of perivascular and interstitial infiltration of tumour cells. Increasing dose of treatment 25 mg/kg was more efficient than 10 mg/kg. Low magnification X: 100 with 100 μm scale bar.

Research topics

  • Synthesis and biological activity

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1016/j.bioorg.2023.107012

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.